chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Nausea, Pain, Pyrexia
Clinical narrative: Chills; Fever; Headache; Body aches; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EW0170) via an unspecified route of administration in the left arm on 17Apr2021 at 08:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. Medical history included thyroid disorder and high blood pressure. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) started on an unknown date for thyroid disorder and unknown if ongoing. The patient previously took metoprolol (MANUFACTURER UNKNOWN) started on an unknown date for unknown indication and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8732) via an unspecified route of administration in the left arm on 27Mar2021 at 15:30 (at the age of 53-year-old) as a single dose for COVID-19 immunisation. On 17Apr2021 at 20:30, about 12 hours after injection, the patient experienced chills, fever, headache, body aches and nausea. The events did not result in doctor or other healthcare professional office or clinic visit, emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, headache, body aches and nausea were recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Pain in extremity, Rash, Rash pruritic
Clinical narrative: Under my left arm (where  got shot) swelled to big enough size. would say it was as big as golf ball and assuming it was a lymph node; Arm could not go straight down and it was very tender; Had a rash covered whole body for a full week. The sun seemed to aggravate the rash; It was a rash that itched; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FP 7533) via an unspecified route of administration in the left arm on 01Apr2021 at 16:15 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included latex allergy and COVID-19. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) on an unknown date and experienced drug allergy. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 06:00, after 24 hours of vaccine, the patient experienced under left arm (where got shot) swelled to big enough size that arm could not go straight down and it was very tender. It was as big as golf ball and patient assumed it was a lymph node. Patient also had a rash covering her whole body for a full week. The sun seemed to aggravate the rash and it was a rash that itched. Therapeutic measures were taken as a result of the event rash and itchy rash and included treatment with BENADRYL. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event under left arm (where got shot) swelled to big enough size that arm could not go straight down and it was very tender, had a rash covering her whole body for a full week and it was a rash that itched was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Vision blurred
Clinical narrative: Vision went suddenly blurry; Moderate headache; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0151) via an unspecified route of administration in the left arm on 15Apr2021 at 09:00 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications included paracetamol (TYLENOL), colecalciferol (VITAMIN D3), curcuma longa rhizome (TURMERIC), unspecified multi-vit and probiotic; all taken for unknown indications from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 15Apr2021 at 22:00, approximately 14 hours after receiving the first vaccine, the patient's vision went suddenly blurry for about 20 minutes. On 15Apr2021, the patient also had a moderate headache that developed about 1-2 hours prior to her vision going blurry. She had never experienced blurry vision before, so this was definitely not ordinary for her. The patient's vision returned to normal, and the following morning, her headache had subsided. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events moderate headache was resolved on 16Apr2021 and the event vision went suddenly blurry was resolved on 15Apr2021 at 22:20.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site pain
Clinical narrative: Injection site soreness; Headache; General fatigue; This is a spontaneous report from a non-contactable consumer. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 17Apr2021 at 10:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. The patient had no known allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 27Mar2021 at 10:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021, the patient experienced injection site soreness, headache and general fatigue. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events injection site soreness, headache and general fatigue was resolving at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain, Pain in extremity
Clinical narrative: Headache; Body aches; Tiredness; Sore entire arm- still sore; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ENO158) via an unspecified route of administration in the left arm on 16Apr2021 at 14:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any medication within two weeks of COVID-19 vaccine. On 16Apr2021 at 14:30, the patient experienced headache, body aches, tiredness, sore entire arm- still sore. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, body aches, tiredness was recovered with sequelae at the time of this report. While the clinical outcome of the event sore entire arm was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis, Pyrexia, Swelling face
Clinical narrative: Fever; The left side of my face was swollen; I had a uncontrolable bloody nose; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unknown age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 17Apr2021 at 09:45 as a single dose for COVID-19 immunisation. Medical history included fruit allergy to blueberries. Concomitant medications included zolpidem tartrate (AMBIEN) and amfetamine aspartate; amfetamine sulfate; dexamfetamine saccharate; dexamfetamine sulfate (ADDERALL) for an unknown indication from an unknown date. The patient previously took acetylsalicylic acid (ASPIRIN) for an unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 08:00, the patient experienced fever, the left side of the face was swollen, and had an uncontrollable bloody nose. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events (unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, the left side of her face was swollen and uncontrollable bloody nose were recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Immune system disorder
Clinical narrative: Shingles diagnosis due to Pfzier shot lowering immune system; Shingles diagnosis due to Pfzier shot lowering immune system; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 11:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications within two weeks of vaccination. The patient previously received acetylsalicylic acid (ASPIRIN) on an unknown date, for unknown indication and experienced upset stomach. The patient did not receive any other vaccines within four weeks prior to the COVID vaccination. On 31Mar2021, at 17:00 the patient experienced shingles diagnosis due to Pfizer shot and lowering immune system. The event resulted in emergency room/department or urgent care visit. Therapeutic measures were taken as a result of lowering immune system and included treatment with injection and prescribed prescription. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event shingles diagnosis due to Pfizer shot lowering immune system was recovering at the time of this report.  No follow-up attempts are required; information about lot number cannot be obtained.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Lymphadenopathy
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Apr2021 at 12:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 16:00, the patient experienced left arm pit pain and swelling of lymph nodes. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events left arm pit pain and swelling of lymph nodes was resolving at the time of this report. No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, SARS-CoV-2 test
Clinical narrative: Weird numbness in right leg, right above knee; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 08Apr2021 at 15:45 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included sickle-cell anemia, blood clot and high blood pressure. The patient did not have any allergies to food, medications, or other products. Concomitant medications included apixaban (ELIQUIS), morphine sulfate ER (MANUFACTURER UNKNOWN) and oxycodone (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date at 03:45 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021, the patient underwent COVID-19 test (nasal swab) and the result was negative. On 11Apr2021, the patient experienced weird numbness in right leg, right above the knee. The event resulted in emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event weird numbness in right leg, right above the knee was not resolved at the time of this report   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Herpes zoster, Neck pain, Oral herpes, Rash macular
Clinical narrative: COVID tongue; gastrointestinal distress; intense neck pain; herpes zoster virus; re-activation of herpes zoster virus, with cold sore; re-activation of herpes zoster virus, with cold sore and red spots on face.; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 12Apr2021 at 15:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy, herpes zoster. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Patient did not receive any medications within two weeks of the COVID-19 vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 15Mar2021 at 16:15 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021, within two days the patient experienced intense neck pain and gastrointestinal distress. On 15Apr2021, within three the patient experienced COVID tongue. On an unknown date in Apr2021, the patient experienced re-activation of herpes zoster virus, with cold sore and red spots on face. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events intense neck pain and gastrointestinal distress, COVID tongue, herpes zoster virus, with cold sore and red spots on face was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Tongue disorder
Clinical narrative: COVID tongue; gastrointestinal distress; intense neck pain; herpes zoster virus; re-activation of herpes zoster virus, with cold sore; re-activation of herpes zoster virus, with cold sore and red spots on face.; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 12Apr2021 at 15:45 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy, herpes zoster. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Patient did not receive any medications within two weeks of the COVID-19 vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 15Mar2021 at 16:15 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021, within two days the patient experienced intense neck pain and gastrointestinal distress. On 15Apr2021, within three the patient experienced COVID tongue. On an unknown date in Apr2021, the patient experienced re-activation of herpes zoster virus, with cold sore and red spots on face. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events intense neck pain and gastrointestinal distress, COVID tongue, herpes zoster virus, with cold sore and red spots on face was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: when lifting something or having arm in certain position a stinging sensation at the injection site; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: En6207) via an unspecified route of administration in the left arm on 17Mar2021 at 16:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. No known allergies were reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 09Apr2021, the patient noticed when lifting something or having arm in certain position a stinging sensation at the injection site. The patient did not notice this until approximately one month after injection. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event when lifting something or having arm in certain position a stinging sensation at the injection site was not recovered at the time of this report.     No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered at inappropriate site, Vaccination site erythema, Vaccination site rash
Clinical narrative: A day later around red bump appeared.; A day later around red bump appeared.; Shot was given to me in wrong location down low on fatty part of my arm and nowhere near the deltoid muscle.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 29Mar2021 at 17:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 08Mar2021 at 17:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 29Mar2021 at 17:45, the patient reported that the shot was given in wrong location down low on fatty part of the arm and nowhere near the deltoid muscle and on 30Mar2021 at 10:00, a day later around red bump appeared. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event around red bump appeared was unknown.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Dizziness, Fatigue, Migraine, Pyrexia
Clinical narrative: 99.7 Fever; Serve migraine; Dizziness; Exhaustion; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 14:00 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease and allergy to gluten. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Mar2021 at 12:30 (at the age of 28-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. On Friday the 16Apr2021, the patient experienced 99.7 fever (unspecified units), severe migraine, dizziness and exhaustion. The fever came on and off both Saturday 17Apr2021 and Sunday 18Apr2021, migraine and dizziness would come and go as frequently as the fever. Exhaustion lasted all three days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, severe migraine, dizziness were recovered on an unknown date in Apr2021; while that of the event exhaustion recovered on 18Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Slight numbness sensation on 1/2 of face; Slight tingling sensation on 1/2 of face; Slight numbness/tingling sensation on 1/2 of body; Slight numbness/tingling sensation on 1/2 of body; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 08Apr2021 at 16:00 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included an allergy to PCN (penicillin). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included unspecified prenatal vitamins, vitamin d nos (MANUFACTURER UNKNOWN), fish oil (MANUFACTURER UNKNOWN) and calcium (MANUFACTURER UNKNOWN); all taken for unknown indications from unknown dates and unknown if ongoing. The patient previously received oseltamivir phosphate (TAMIFLU), paracetamol; oxycodone hydrochloride (PERCOCET), azithromycin (MANUFACTURER UNKNOWN) and clindamycin (MANUFACTURER UNKNOWN) and experienced drug allergies. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccination. On 08Apr2021 at 16:30, the patient experienced slight numbness/tingling sensation on half of face/body that started immediately after receiving the shot and continued for days. The events resulted in a doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight numbness/tingling sensation on half of face/body was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles (herpes zoster) infection; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 07Apr2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included GERD (gastroesophageal reflux disease) and anxiety. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included paroxetine hydrochloride (PAXIL) and lansoprazole (MANUFACTURER UNKNOWN) both taken for unspecified indications from unknown dates and unknown if ongoing. The patient previously received cefaclor (CECLOR) (antibiotic) and experienced a drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on an unknown date in Mar2021 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccination. On 18Apr2021 at 08:00 the patient experienced shingles (herpes zoster) infection. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of event which included treatment with valaciclovir (MANUFACTURE UNKNOWN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event shingles (herpes zoster) infection was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Anosmia, SARS-CoV-2 test
Clinical narrative: I lost my sense of smell three days after I had gotten my first shot, it has not returned.; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the right arm on 12Apr2021 at 18:15 (at the age of 22-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications were not taken within two weeks of vaccination. The patient had received other vaccines within four weeks prior to the vaccination which included measles vaccine, mumps vaccine, rubella vaccine (MMR) on 29Mar2021 in the left arm for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient lost his sense of smell on 15Apr2021 at 12:00, three days after he had gotten his first shot, it had not returned. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On 19Apr2021, the patient underwent LUMIRADX SARS-COV-2 AG test for COVID- 19 via nasal swab and the result was negative. The clinical outcome of the event lost sense of smell three days after the patient had gotten his first shot, it had not returned was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, SARS-CoV-2 test
Clinical narrative: Dizziness (room spinning) when laying on left side and  when making quick movement up and down; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 09Apr2021 at 11:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient did not have any allergies to food, medications, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included vitamins nos (VITAMINS) for an unknown indication from an unknown date. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021, the patient experienced dizziness (room spinning) when laying on left side and when making quick movement up and down. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the event dizziness (room spinning) when laying on left side and when making quick movement up and down was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Nausea
Clinical narrative: Experienced fatigue; Dizziness; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO153) via an unspecified route of administration in the right arm on 09Apr2021 at 10:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included nitrofurantoin (NITROFURANTOIN MONO/MAC) for unknown indication, from an unknown date and unknown if ongoing. On 09Apr2021 at 16:00, about 5 hours after shot the patient experienced fatigue, dizziness and nausea. Fatigue continued for 24 hours. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event fatigue was recovered on 10Apr2021 at 16:00 (24 hours). The clinical outcome of the events dizziness and nausea were recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 10Apr2021 at 11:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included prenatal vitamins (unspecified) from on an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 20Mar2021 at 11:00 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) on an unknown date and experienced drug allergy. On 13Apr2021 at 00:00, the patient was diagnosed with shingles. The adverse event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the reported event and included treatment with antivirals (unspecified). The clinical outcome of the event shingles was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Lymphadenopathy, Pain, Rash
Clinical narrative: Rash at injection site (upper right arm); Swollen glands in right armpit; Rash in armpit; Tiredness; Headache; Aches; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 17Apr2021 at 09:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included multivitamins (MANUFACTURER UNKNOWN) from an unknown date from an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 27Mar2021 at 09:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 10:00, the patient experienced rash at injection site; upper right arm, swollen glands in right armpit with rash in armpit, tiredness, aches and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash at injection site; upper right arm, swollen glands in right armpit with rash in armpit, tiredness, aches and headache was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: Rash at injection site (upper right arm); Swollen glands in right armpit; Rash in armpit; Tiredness; Headache; Aches; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 17Apr2021 at 09:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included multivitamins (MANUFACTURER UNKNOWN) from an unknown date from an unspecified indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 27Mar2021 at 09:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 18Apr2021 at 10:00, the patient experienced rash at injection site; upper right arm, swollen glands in right armpit with rash in armpit, tiredness, aches and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events rash at injection site; upper right arm, swollen glands in right armpit with rash in armpit, tiredness, aches and headache was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Hyposmia
Clinical narrative: Decreased sense of smell; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 09Apr2021 at 14:30 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to lilacs. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included duloxetine (MANUFACTURER UNKNOWN) 60 mg and unspecified birth control; both for unspecified indication and from unknown date and unknown if ongoing. On 17Apr2021, the patient experienced decreased sense of smell- can only smell smoke constantly. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event decreased sense of smell- can only smell smoke constantly was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling hot, Paraesthesia
Clinical narrative: Experienced a warm feeling that went up along neck and across the left side of face (the same side the vaccine on).; Experienced a tingly feeling that went up along neck and across the left side of face (the same side the vaccine on); This is a spontaneous report from a contactable consumer, the patient. A 39-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in left arm on 19Apr2021 at 10:15 (at the age of 39-years old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 19Apr2021 at 10:45, 20 minutes after receiving the vaccination, the patient experienced a warm, tingly feeling that went up along his neck and across the left side of his face (the same side the patient's the vaccine on). After an hour the patient felt 90% better and five hours later, the patient had still felt a low sense of tingly, warm feeling along his left side of the neck and face. Since the vaccination, the patient had not been tested for COVID-19.  The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of events. The clinical outcome of the events, warm and tingly feeling in neck and across the left side of face was recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: hands got itchy, both the outside and the inside, in between fingers and  palm; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 13:15 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included Irritable Bowel Syndrome (IBS) and hay fever. The patient was allergic to penicillin. Concomitant medications included lansoprazole (MANUFACTURER UNKNOWN), citalopram (MANUFACTURER UNKNOWN) and fexofenadine (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021, 4 days after the second vaccination, the patient experienced itchy hands. She had a penicillin allergy and this event was causing much more severe itching. This was just in her hands, both the outside and the inside, in between fingers and palm itched the most. The itchiness was coming and going but was present at the time of this report. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event itchy hands both the outside and the inside, in between fingers and palm was not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Influenza, Oropharyngeal pain, Pain, Pyrexia
Clinical narrative: Flu symptoms; Headache; Runny nose; Slight fever; Sore throat; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the arm left on 18Apr2021 at 10:30 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 20:00, the patient experienced flu symptoms, headache, runny nose, slight fever, sore throat and body aches. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events flu symptoms, headache, runny nose, slight fever, sore throat and body aches were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea
Clinical narrative: Flu symptoms; Headache; Runny nose; Slight fever; Sore throat; Body aches; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the arm left on 18Apr2021 at 10:30 (at the age of 46-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications were not reported. The patient had no known allergies to medications, food or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 20:00, the patient experienced flu symptoms, headache, runny nose, slight fever, sore throat and body aches. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events flu symptoms, headache, runny nose, slight fever, sore throat and body aches were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.